Snapshot from Jul 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Ipsen acquires Memo Therapeutics
Business acquisition

Ipsen acquires Memo Therapeutics

Analysis based on 7 articles · First reported Jul 01, 2026 · Last updated Jul 10, 2026

Sentiment
15
Attention
3
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The acquisition strengthens Ipsen's rare disease pipeline with a promising first-in-class asset. The deal is expected to close in Q3 2026 and is included in Ipsen's full-year guidance.

biotechnology pharmaceuticals
Event Summary

French drugmaker Ipsen has agreed to acquire Swiss biotech Memo Therapeutics for up to €700 million ($800 million), including €200 million upfront and milestone payments. The deal focuses on potravitug, a Phase II monoclonal antibody targeting BK polyomavirus-associated nephropathy (BKPyVAN) in kidney transplant recipients. Potravitug has FDA fast-track and EU orphan drug designations. Ipsen plans to initiate a pivotal Phase II/III trial later this year. Memo's non-potravitug assets will be transferred to a new company, Memo Therapeutics, retained by Memo's shareholders. The acquisition is Ipsen's second in three days, following the $1.75 billion purchase of Kartos Therapeutics.

Key Actions
100 Ipsen acquired Memo Therapeutics
80 Ipsen acquired Kartos Therapeutics
50 Memo Therapeutics presented phase 2 data
30 Ipsen granted fast-track designation United States — Food and Drug Administration
20 European Union granted orphan drug designation Memo Therapeutics
10 Memo Therapeutics transferred non-potravitug assets Memo Therapeutics
Entities Involved
stock
Ipsen
Ipsen acquires Memo Therapeutics to bolster its rare disease pipeline with potravitug, a Phase II antibody for BKPyVAN. The deal follows Ipsen's acquisition of Kartos Therapeutics, reflecting its strategy of external innovation.
Importance 100.0 Sentiment 15.0
priv
Memo Therapeutics
Memo Therapeutics is acquired by Ipsen for up to €700 million. Its lead asset, potravitug, gains access to Ipsen's rare disease expertise. Non-potravitug assets are transferred to Memo Therapeutics.
Importance 100.0 Sentiment 80.0
priv
Kartos Therapeutics
Kartos Therapeutics was acquired by Ipsen earlier the same week for up to $1.75 billion, adding navtemadlin to Ipsen's oncology pipeline.
Importance 20.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
The FDA granted fast-track designation to potravitug in 2023, facilitating its development for BKPyVAN.
Importance 20.0 Sentiment 0.0
alliance
European Union
The EU granted orphan drug designation to potravitug in December 2025, providing incentives for development.
Importance 15.0 Sentiment 0.0
curr
European Union — Euro
The deal is denominated in euros, with upfront payment of €200 million and total potential value of €700 million.
Importance 10.0 Sentiment 0.0
per
Christelle Huguet
Christelle Huguet, Ipsen's Head of R&D, highlighted the strategic value of potravitug for Ipsen's rare disease pipeline.
Importance 10.0 Sentiment 0.0
per
Erik van den Berg
Erik van den Berg, CEO of Memo Therapeutics, expressed enthusiasm about Ipsen's ability to advance potravitug.
Importance 10.0 Sentiment 0.0
exch
Euronext Paris
Ipsen shares closed 2.30% higher on Euronext Paris following the announcement.
Importance 5.0 Sentiment 0.0
curr
United States — United States dollar
The deal value is approximately $800 million, with upfront payment of $228 million.
Importance 5.0 Sentiment 0.0
stock
CSL Limited
CSL had a $328 million pact with Memo Therapeutics earlier in 2026 to collaborate on recombinant polyclonal immunoglobulin technology, but this is not directly affected by the acquisition.
Importance 5.0 Sentiment 0.0
per
Darshana Dadhania
Darshana Dadhania, medical director at Weill Cornell Medicine, emphasized the clinical challenge of BKPyVAN and the need for effective therapy.
Importance 5.0 Sentiment 0.0
Relationships
United States — Food and Drug Administration related ↔ European Union
European Union related ↔ Euronext Paris
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.